# CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct04176848/  
OnCo record `nct04176848` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of CFI-400945 run by Canadian Cancer Trials Group, active and no longer recruiting.

## Summary

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer is a phase 2 interventional study registered as NCT04176848 by Canadian Cancer Trials Group, with 15 participants planned, started 2020-08-10. Conditions recorded: Breast Cancer. Interventions recorded: CFI-400945 and Durvalumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04176848
- Phase: 2
- Setting: A Phase II Study of CFI-400945 and Durvalumab in Patients With Advanced/Metastatic Triple Negative Breast Cancer (TNBC)
- Sponsor: Canadian Cancer Trials Group
- Enrolled: 15

## Sources

- ClinicalTrials.gov NCT04176848: https://clinicaltrials.gov/study/NCT04176848

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [CFI-400945](https://onco.cc/drugs/cfi-400945/)
- companies: [Treadwell Therapeutics](https://onco.cc/companies/treadwell-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct04176848.json